Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 6,028

Document Document Title
WO/2008/073958A3
The present invention is directed to substituted benzothiadiazinedioxide derivatives of formula (I) :or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containin...  
WO/2008/111588A1
Disclosed is a method for efficiently producing difluoromethanebis(sulfonylfluoride). Specifically disclosed is a method for producing a compound (1) wherein a compound (2F) is fluorinated. The compound (2F) is obtained by reacting a com...  
WO/2008/110278A2
The use of N2-phenylamidines of general formula (I) as herbicides is disclosed. In said general formula (I) R2, R3, R4, R5 and R6 are various groups and A is a bond or various single- or multi-atom bridge elements.  
WO/2008/111473A1
Disclosed is a compound represented by the formula (1) below or a pharmaceutically acceptable salt thereof. [chemical formula 1] (1) (In the formula, the configuration of a carbon atom marked with an asterisk (*) is R; R1 represents a hy...  
WO/2008/107677A2
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X is an oxygen or sulphur atom A is CH(R6)-, -O- or NR7 or when A is NR7, then R1 and NR7 can together form a ring such that R1 and R7 are (CH2)n...  
WO/2008/105607A1
A novel heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-r...  
WO/2008/005764A3
The present invention is directed to an insecticidal composition comprising zeta- cypermethrin: a) prepared by an epimerization process, and b) containing a residual amount of an epimerization catalyst, and glycerine, wherein the zeta-cy...  
WO/2008/101665A1
The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection.  
WO/2008/102348A1
Novel Alpha-halo- and Alpha-alkyl-cyclopropylcarboxy compounds, and uses of these and related compounds in the treatment of a variety of neurological diseases and disorders, and particularly epilepsy, are provided.  
WO/2008/102908A1
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by the general formula (1) below, or an agrochemically acceptable salt thereof. (In the formula, Q represents -N(R5)SO2R6, wherein ...  
WO/2008/045558A3
Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and use thereof to treat or prevent diseases associated with monocyte a...  
WO/2008/093674A1
Disclosed is a compound represented by the formula (I) below or a salt thereof. In the formula, ring A represents a benzene ring, a thiophene ring or a pyridine ring; Ra represents a hydrogen atom, a halogen atom, an alkyl group or an al...  
WO/2008/032858A3
A thiadiazole compound represented by the formula (I): wherein R is a hydrogen atom, an optionally substituted C1-C7 chain hydrocarbon group etc., Z is an oxygen atom or a sulfur atom, X is a -NR2R3 group etc., R2 and R3 each independent...  
WO/2008/073956A3
The present invention is directed to cyclic sulfonamide derivatives of formula (I): or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their u...  
WO/2008/084872A1
Disclosed is a hydrazone derivative represented by the formula [I] below or a pharmacologically acceptable salt thereof, which is useful as a glucokinase activator. (In the formula, ring A represents an aryl or a heteroaryl; T represents...  
WO/2008/036652A3
The present invention is directed to amidino heterocyclic compounds of formula Ia and IIa which are modulators of indoleamine 2, 3 - dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.  
WO/2008/077507A1
The present invention relates to heteroaryl-substituted carboxamides of the formula (I) in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) syntha...  
WO/2008/078674A1
Disclosed is a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, wherein a carbon atom having an asterisk has an R-configuration; R1 and R2 independently represent a hydrogen atom, a halogen atom, an ...  
WO/2008/077138A1
Compounds of formula (I): and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of G...  
WO/2008/075026A1
The present invention provides compounds of formula (I) (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein Ra, Rb, R1, R2, R3, R4, R5, R6 and R29 are as defined in the specification, processes ...  
WO/2008/076754A2
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).  
WO/2008/074132A1
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...  
WO/2008/073958A2
The present invention is directed to substituted benzothiadiazinedioxide derivatives of formula (I) :or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containin...  
WO/2008/073459A1
The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, ...  
WO/2008/073956A2
The present invention is directed to cyclic sulfonamide derivatives of formula (I): or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their u...  
WO/2008/071421A1
Nitroderivatives of carbonic anhydrase inhibitors having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration...  
WO/2008/061781A1
The invention provides novel 1,2,4-thiadiazole derivatives useful for preventing or treating an α-synucleopathy such as Parkinson's disease, as well as pharmaceutical compositions including them as biologically active ingredients, and m...  
WO/2008/042928A3
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of uti...  
WO/2008/059025A1
The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions asso...  
WO/2008/059128A1
The present invention relates to new phenylic derivatives, wherein these products exhibit a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. They are of particular interest for treating patho...  
WO/2008/036308A3
Provided herein are Heterocyclic Compounds having the following structure: Formula (I) wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or p...  
WO/2008/050167A1
The present invention relates to new sulfonamide derivatives of formula (I), wherein R1-R8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective a...  
WO/2008/049864A1
This invention relates to oxadiazolyl and thiadiazolyl derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the trea...  
WO/2008/047138A2
The present invention provides histone deacetylase inhibitors of general formula (I), a process for the preparation of such compounds and uses of the compounds in medicine, especially in the treatment of cancers: in which R1 is an option...  
WO/2008/022286A3
The present invention relates to compounds of Formula I below and their tautomers or pharmaceutically acceptable salts, compositions and methods of uses thereof.  
WO/2008/045558A2
Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and use thereof to treat or prevent diseases associated with monocyte a...  
WO/2008/020256A3
(I) The present invention is related to new 3,4-dihydroberizo[1,2,3]thiadiazine-1,1-dioxide derivatives of the Formula (I), medicaments containing said new compounds, process for the preparation thereof and the use of said derivatives in...  
WO/2007/026376A3
This invention relates to a process for the preparation and purification of a pure crystalline Hydrochlorothiazide with overall purity 99.9% or greater and single impurity below 0.1%. This is a two step process. In first step crude hydro...  
WO/2008/042928A2
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of uti...  
WO/2008/038841A1
Disclosed is a compound represented by the general formula [I], a pharmaceutically acceptable salt thereof, or a solvate of the compound or the salt. The compound is excellent in selective TACE-inhibiting activity. Therefore, a pharmaceu...  
WO/2008/039023A1
A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related ...  
WO/2008/014199A3
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...  
WO/2008/036652A2
The present invention is directed to amidino heterocyclic compounds of formula Ia and IIa which are modulators of indoleamine 2, 3 - dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.  
WO/2008/036308A2
Provided herein are Heterocyclic Compounds having the following structure: Formula (I) wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or p...  
WO/2008/019090A3
The invention provides compounds formulae I-III, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an act...  
WO/2007/115058A3
Compounds of the formula (I) are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as...  
WO/2008/033455A2
Disclosed are compounds and pharmaceutically acceptable salts of formula (I) : wherein A, B, D, L1 L2, R2, RA, RB, X, m, n, and p are as defined herein, which are useful in the treatment of metabolic disorders related to insulin resistan...  
WO/2008/031534A1
Novel compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N- oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), t...  
WO/2008/032858A2
A thiadiazole compound represented by the formula (I): wherein R is a hydrogen atom, an optionally substituted C1-C7 chain hydrocarbon group etc., Z is an oxygen atom or a sulfur atom, X is a -NR2R3 group etc., R2 and R3 each independent...  
WO/2008/016692A3
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activate...  

Matches 451 - 500 out of 6,028